ICU admission rates in Istanbul following the addition of favipiravir to the national COVID-19 treatment protocol
| dc.authorid | 0000-0002-5173-3867 | |
| dc.authorid | 0000-0002-0255-5777 | |
| dc.contributor.author | Guner, Abdullah Emre | |
| dc.contributor.author | Surmeli, Aral | |
| dc.contributor.author | Kural, Kemal | |
| dc.contributor.author | Yilmaz, Habip | |
| dc.contributor.author | Kocayigit, Erdogan | |
| dc.contributor.author | Sahin, Esra | |
| dc.contributor.author | Alkan, Perihan | |
| dc.date.accessioned | 2025-05-10T19:52:43Z | |
| dc.date.issued | 2021 | |
| dc.department | İstanbul Medeniyet Üniversitesi | |
| dc.description.abstract | OBJECTIVE: The objective of this study was to understand the observational relationship between adoption of favipiravir into the national COVID-19 treatment protocol and intensive care unit (ICU) admission rates in Istanbul due to COVID-19. METHODS: Data were harvested from the Public Health Management System-HSYS, which collate centrally the records of all known cases of COVID-19. The total number of cases, numbers admitted to ICU, and number undergoing intubation were compared between 2 time periods: 11th of March, the date on which the first case in Turkey was confirmed, to 30th of March; and March 30, to 10th of April, 5 days after Favipiravir was introduced into the treatment algorithm when, the records were examined. RESULTS: The percentage of patients requiring ICU admission diminished from 24% to 12%, whilst the percentage intubated fell from 77% to 66%. These differences were both statistically significant. CONCLUSION: The addition of favipiravir to the national COVID-19 treatment protocol may explain this rapid decrease in the rate of ICU admissions and intubation. | |
| dc.identifier.doi | 10.14744/nci.2021.60420 | |
| dc.identifier.endpage | 123 | |
| dc.identifier.issn | 2148-4902 | |
| dc.identifier.issn | 2536-4553 | |
| dc.identifier.issue | 2 | |
| dc.identifier.pmid | 33851074 | |
| dc.identifier.scopusquality | Q4 | |
| dc.identifier.startpage | 119 | |
| dc.identifier.trdizinid | 410037 | |
| dc.identifier.uri | https://doi.org/10.14744/nci.2021.60420 | |
| dc.identifier.uri | https://search.trdizin.gov.tr/tr/yayin/detay/410037 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.14730/12503 | |
| dc.identifier.volume | 8 | |
| dc.identifier.wos | WOS:000637256700002 | |
| dc.identifier.wosquality | N/A | |
| dc.indekslendigikaynak | Web of Science | |
| dc.indekslendigikaynak | TR-Dizin | |
| dc.indekslendigikaynak | PubMed | |
| dc.language.iso | en | |
| dc.publisher | Kare Publ | |
| dc.relation.ispartof | Northern Clinics of Istanbul | |
| dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | |
| dc.rights | info:eu-repo/semantics/openAccess | |
| dc.snmz | KA_WOS_20250302 | |
| dc.subject | COVID-19 | |
| dc.subject | favipiravir | |
| dc.subject | intensive care unit | |
| dc.title | ICU admission rates in Istanbul following the addition of favipiravir to the national COVID-19 treatment protocol | |
| dc.type | Article |
Dosyalar
Orijinal paket
1 - 1 / 1










